Age Management Therapeutics
PHYSICIAN MANAGED PERSONALIZED MEDICINE PROGRAMS TRANSFORMATIVE MEDICINE…TRANSFORMATIVE HEALTHCARE
Founded in 2001, the IntraTherapies Institute is a catalyst in the evolution of health management and the integration of Longevity Science and Personalized Medicine within its group of proactive health enhancement programs.
Targeting the neurobiology of aging, IntraTherapies is committed to the highest standards in providing a platform for both preventive as well as interventional healthcare programs, IntraTherapies’ objectives are directed toward a clinical architecture addressing primary age-related disease categories and therapeutic processes on multiple levels of the healthcare continuum.
Within a medical framework comprising the specialties of neurology, endocrinology, oncology, hematology, and immunology, we strive for a comprehensive but cost effective approach enabling a new category of healthcare, Age Management Therapeutics. From both a preventive and interventional perspective, we enable an evidence-based platform of comprehensive care while providing an innovative clinical environment to foster important new medical discoveries. Founded in 2001, the IntraTherapies Institute actively pursues the ‘leading edge’ but guided by stringent oversight from a committed medical team interested in the progression from present day clinical choices to a near future of significant health improvement within current time frames for patients.
The ultimate objectives are to accelerate the availability of evidence-based clinically validated treatments to a broader population seeking the most promising, safe and effective medical programs for disease prevention, disease intervention and enhanced health.
We identify our primary Age Management Therapeutics programs within two categories of conjoined healthcare:
- Neurosystemic Medicine
IntraTherapies addresses three of the primary components of disease which present increasing challenges to US and global healthcare:
- Age-Related Neurodegenerative Disorders
- Late Stage Cancer Therapeutics
- Auto Immune and Inflammatory Diseases
IntraTherapies initial clinical objectives for patients provide a basis for overall equilibrium in health status enabled by evidence-based Neurosystemic Medicine. This approach is then conjoined with longevity science, pharmacogenomics and personalized medicine. The Age Management Therapeutics programs continue, further extending to preventive and interventional Epigenetic Cancer Therapeutics, with oncologist guided programs for each patient’s condition inclusive of Quality of Life factors. IntraTherapies Neurosystemic and Epigenetic therapeutic platforms utilize clinically-validated modalities directed toward optimal neurosystemic health, cancer preventive therapeutics, as well as late stage cancer interventional programs addressing a broad range of cancer categories.
IntraTherapies clinical alliances are also pursuing research in the emerging area of cancer preventive and interventional vaccines.
Creating an environment that resonates with responsible clinical innovation is our central mandate and evolving a new plateau in personalized medicine our primary mission.
PHYSICIAN MANAGED PERSONALIZED MEDICINE PROGRAMS
CATEGORY 1 | NEUROSYSTEMIC MEDICINE I AGE MANAGEMENT THERAPEUTICS
This program is clinically directed toward to overall neuroendocrine support and is based on the primary principles of neuroendocrinology within a clinical program of personalized medicine. Neurosystemic Medicine addresses a spectrum of predictive age–related degenerative disorders and central nervous system functions with a group of Neurometabolic / Neuroendocrine regulating programs for optimal neuro-systemic effect coupled with neuro protective factors targeting cognitive function with potential neuroimmune benefits to support healthy aging.
CATEGORY 2 | CANCER PREVENTIVE THERAPEUTICS
This program is clinically directed toward Enhanced Intracellular Genetic Immunity (EIGI) via DNA Programmable Genetic Pharmacology.
CATEGORY 3 | EPIGENETIC CANCER THERAPEUTICS
IntraTherapies epigenetic programs are based on molecular cancer genetics and DNA Programmable Genetic Pharmacology, in conjunction with targeted combination therapies and pathway-specific programs targeted to achieve broader cancer interventional effect with enhanced safety at the cellular level, absent adverse impact on major cellular pathways. This approach, based on extensive human and other mammal studies noted below, appears to result in notable reduction of treatment toxicity levels across primary solid tumor cancer groups, specifically, Breast, Colon, Prostate, Non Small Cell Lung, Renal, and Ovarian cancer when further combined with Low Dose Metronomic Chemotherapy. All IntraTherapies treatment programs are based on oncologist / hematologist assessment of patient history, current treatment and health profile.
IECT - IntraTherapies Epigenetic Cancer Therapeutics is a Clinical Protocol based on Molecular cancer genetics and DNA Programmable Genetic Pharmacology directed toward inhibiting the Growth and Replication of Human Cancer Cells, Administered as a Monotherapy or Conjunctively with Metronomic Low Dose Chemotherapy.
Epigenetic Cancer Therapeutics is comprised of preventive and late stage cancer interventional therapeutic programs focused on enhanced intracellular genetic immunity. This is achieved by the integration of epigenetic programs combined with specific standard of care oncology medications with clinically-validated significantly reduced toxicity levels achieved via Metronomic Low Dose Chemotherapy.
Provided as a monotherapy or within a conjunctive treatment protocol, IntraTherapies Epigenetic Cancer Therapeutics has clinically demonstrated the ability to inhibit the growth, replication and proliferation of human cancer cells via DNA Methyltransferase Inhibitors. (See list of medical research institutions and recognized peer-reviewed publications below)
Additional neurosystemic clinical objectives include the measurable achievement of enhanced Quality of Life in managing Mood Disorders in Chronically ill patients.
* Note: These statements are based on published medical research data from the National Cancer Institute and other independent accredited medical institutions in peer-reviewed oncology / hematology publications worldwide which include:
- Indiana University School of Medicine; Indiana University Cancer Center - Departments of Surgery and Biochemistry/Molecular Biology
- Walther Oncology Center; Cancer Epigenetics Laboratory
- Spanish National Cancer Centre-Molecular Pathology Program
- Osaka University Graduate School of Medicine – Japan.
Published data referenced in this section appear in clinical oncology journals including:
- Cancer Research / American Association for Cancer Research;
- Current Opinion in Oncology, Journal of Pharmacological Sciences
- Elsevier Cancer Letters,
- Molecular Cancer Therapeutics
- Modern Pathology
- JNCI - Journal of the National Cancer Institute
CATEGORY 4 | PAIN MANAGEMENT THERAPEUTICS
This program is clinically directed toward Interventional Regulation of neuro-receptor and inflammation pathways for mediating chronic pain conditions but also including degenerative osteo-arthritis, TMJ, post-traumatic surgical pain as well as neck / back / spine disorders, chronic scoliosis, and extending to overall Intra-systemic mediation of multi-source chronic pain within the musculo-skeletal network.
CATEGORY 5 | MIGRAINE INTERVENTIONAL THERAPEUTICS
This program is clinically directed toward Neuro receptor channel modulation for aura and non-aura-based chronic migraine and headache disorders.
CATEGORY 6 | SLEEP ENHANCEMENT THERAPEUTICS
This program is clinically directed toward targeted regulation of sleep disturbances related to circadian and other neuro mechanisms to alleviate acute and chronic insomnia as well as other inhibitors related to quality / continuity of sleep, and lack of restorative sleep.
CATEGORY 7 | RHEUMATOLOGY AND IMMUNO-RESTORATIVE THERAPEUTICS
This program is clinically directed to Rheumatoid Arthritis and all Immuno-Degenerative, Autoimmune and inflammatory Disorders resulting from the pathophysiologies of immuno-systemic compromise and chronic inflammation. This regimen is further directed toward inflammatory diseases such as Fibromyalgia, Lupus, Epstein-Barr, Chronic Fatigue Syndrome and the spectrum of approximately 105 immunity-related conditions.
CATEGORY 8 I NEUROOPTIC THERAPEUTICS
This program is clinically directed toward Vision Optimization and Vascular Support for Long Term Eye Health.
CATEGORY 9 I SPORTS AND PERFORMANCE THERAPEUTICS
This program is clinically directed toward Optimization of Circulatory, Vascular and Pulmonary Function with stabilization of Central and Sympathetic Nervous System.
CATEGORY 10 | INTRACELLULAR DERMAL REGENERATIVE THERAPEUTICS
This program is clinically directed toward anti-inflammatory vascular enhancement. It may provide dynamic oxygenation throughout all dermal/epidermal pathways.